Formulations and methods of treating inflammatory bowel disease

Details Formulations and methods of treating inflammatory bowel disease Formulations and methods of treating inflammatory bowel disease

2011-04-19

2011-04-19

Nolan, Jason M (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ortho-hydroxybenzoic acid or derivative doai

C514S150000, C514S160000, C514S161000, C514S162000, C514S163000, C514S164000, C514S165000, C514S166000

Reexamination Certificate

active

07928092

ABSTRACT:
Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.

REFERENCES:
patent: 4374932 (1983-02-01), Pitzele et al.
patent: 4496553 (1985-01-01), Halskov
patent: 4559330 (1985-12-01), Agback et al.
patent: 4591584 (1986-05-01), Agback
patent: 4608048 (1986-08-01), Cortese et al.
patent: 4627851 (1986-12-01), Wong et al.
patent: 4693895 (1987-09-01), Wong et al.
patent: 4705515 (1987-11-01), Wong et al.
patent: 4880794 (1989-11-01), Halskov
patent: 4904474 (1990-02-01), Theeuwes et al.
patent: 4980173 (1990-12-01), Halskov
patent: 5041431 (1991-08-01), Halskov
patent: 5482718 (1996-01-01), Shah et al.
patent: 5505966 (1996-04-01), Edman et al.
patent: 5519014 (1996-05-01), Borody
patent: 5541170 (1996-07-01), Rhodes et al.
patent: 5541171 (1996-07-01), Rhodes et al.
patent: 5681584 (1997-10-01), Savastano et al.
patent: 5716648 (1998-02-01), Halskov et al.
patent: 5840332 (1998-11-01), Lerner et al.
patent: 5866619 (1999-02-01), Sintov et al.
patent: 6004581 (1999-12-01), Jepsen et al.
patent: 6277412 (2001-08-01), Otterbeck
patent: 6506407 (2003-01-01), Watanabe et al.
patent: 6551620 (2003-04-01), Otterbeck
patent: 6602915 (2003-08-01), Uhrich
patent: 6733789 (2004-05-01), Stark et al.
patent: 6897205 (2005-05-01), Beckert et al.
patent: 6962717 (2005-11-01), Huber et al.
patent: 7737133 (2010-06-01), Devane et al.
patent: 2001/0026807 (2001-10-01), Watts
patent: 2001/0036473 (2001-11-01), Scott et al.
patent: 2002/0098235 (2002-07-01), Dittmar et al.
patent: 2002/0192282 (2002-12-01), Beckert et al.
patent: 2005/0090473 (2005-04-01), Devane et al.
patent: 2006/0223787 (2006-10-01), Devane et al.
patent: 0 140 848 (1985-05-01), None
patent: 0 453 001 (1991-10-01), None
patent: 1 101 490 (2001-05-01), None
patent: 2 692 484 (1993-12-01), None
patent: WO 95/16451 (1995-06-01), None
patent: WO 00/76481 (2000-12-01), None
patent: WO 02/17887 (2002-03-01), None
“Asacol® (mesalamine) Delayed-Release Tablets,” Asacol (mesalamine), pp. 1-8, 2000.
“Azulfidine® sulfasalazine tablets, USP,” pp. 1-18, 2002.
Ardizzone, S. et al., “Is Maintenance Therapy Always Necessary for Patients With Ulcerative Colitis in Remission?,”Aliment Pharm. Ther., vol. 13, No. 3, pp. 373-379, (1999).
Basit et al., “Perspectives on Colonic Drug Delivery,”Business Briefing: Pharmatech, pp. 185-190 (2003).
Bondesen, S. et al., “5- Aminosalicylic Acid in Patients with an Ileo-Rectal Anastomosis A Comparison of the Fate of Sulfasalazine and Pentasa,”Eur. J. Clin . Pharmacol., vol. 31, pp. 23-26, (1986).
Bondesen, S. et al., “Steady-State Kinetics of 5-Aminosalicylic Acid and Sulfapyridine During Sulfasalazine Prophylaxis in Ulcerative Colitis,”Scan. J. Gastroentero., vol. 21, No. 6, pp. 693-700, (1986).
Bondesen, S. et al., “Pharmacokinetics of 5-Aminosalicylic Acid in Man Following Administration of Intravenous Bolus and Per Os Slow-Release Formulation,”Digest. Dis. Sci., vol. 36, No. 12, pp. 1735-1740, (1991).
Bresci, G. et al., “Long-Term Therapy With 5-Aminosalicylic Acid in Crohn's Disease: is it Useful? Our Four Years Experience,”Int. J. Clin. Pharm. Res., vol. XIV, No. 4, pp. 133-138, (1994).
Brignola, C. et al., “Placebo-Controlled Trial of Oral 5-ASA in Relapse Prevention of Crohn's Disease,”Digest. Dis. Sci., vol. 37, No. 1, pp. 29-32, (1992).
Brunner, M. et al., “Gastrointestinal Transit and 5-ASA Release From A New Mesalazine Extended-Release Formulation,”Aliment Pharm. Ther., vol. 17, pp. 395-402, (2003).
Brunner, M. et al., “Gastrointestinal Transit and Release of 5-Aminosalicylic Acid From153Sm-Labelled Mesalazine Pellets vs. Tablets in Male Healthy Volunteers,”Aliment Pharm. Ther., vol. 17 pp. 1163-1169, (2003).
Campieri, M. et al., “Oral Beclometasone Dipropionate in the Treatment of Extensive and Left-Sided Active Ulcerative Colitis: A Multicentre Randomised Study,”Aliment Pharm. Ther., vol. 17, pp. 1471-1480 (2003).
Chourasia, M.K. et al., “Pharmaceutical Approaches to Colon Targeted Drug Delivery Systems,”J. Pharm. Pharmaceut Sci., vol. 6(1) pp. 33-66, (2003).
Christensen, L. A. et al., “5-Aminosalicylic Acid Derivatives. Clinical and Pharmaceutical Evaluation,”Neth J. Med., vol. 35, Suppl. 1:S3:10, (1989).
Christensen, L. A. et al., “Topical and Systemic Availability of 5-Aminosalicylate: Comparisons of Three Controlled Release Preparations in Man,”Aliment Pharm. Ther., vol. 4, pp. 523-533, (1990).
Christensen, L. et al., “Bioavailability of 5-Aminosalicylic Acid from Slow Release 5-Aminosalicylic Acid Drug and Sulfasalazine in Normal Children,”Digest. Dis. Sci., vol. 38, No. 10, pp. 1831-1836, (1993).
Christensen, L. A. et al., “Comparative Biovailability of 5-Aminosalicyclic Acid From a Controlled Release Preparation and an Azo-bond Preparation,”Aliment Pharm. Ther., vol. 8, pp. 289-294, (1994).
Christensen, L. et al., “5-Aminosalicylic Acid Containing Drugs Delivery, Fate, and Possible Clinical Implications in Man,”Dan. Med. Bull., vol. 47, No. 1, pp. 20-41, (2000).
Clemett, D. et al., “Prolonged-Release Mesalazine A Review of Its Therapeutic Potential in Ulcerative Colitis and Crohn's Disease,”Drugs, vol. 59 No. 4, pp. 929-956, (2000).
Corey, A. E. et al., “Biovailabily of single and Multiple Dose of Enteric-Coated Mesalamine and Sulphasalazine,”J. Int. Med. Res., vol. 18, pp. 441-453, (1990).
Davaran, S. et al., “Synthesis and Characterization of Methacrylic Derivatives of 5-Amino Salicylic Acid with pH-Sensitive Swelling Properties,”AAPS PharmaSciTech, vol. 2 (4) article 29 (2001).
Devane, J. et al., “Distal Ileum and Colon: Targeted Sites for 5-ASA Release,”Eur. J. Drug Metab. Phamacokinet, Spec., No. 3, pp. 300-303, (1991).
Dijkstra, G. et al., “Blockade of NF-κB Activation and Donation of Nitric Oxide: New Treatment Options in Inflammatory Bowel Disease?,”Scan. J. Gastroentero., Suppl. 236 (2002).
“Dipentum® olsalazine sodium capsules,” pp. 1-17, 2001.
Ewe, K. et al., “Inflammation Does Not Decrease Intraluminal pH in Chronic Inflammatory Bowel Disease,”Digest. Dis. Sci., vol. 44, No. 7, pp. 1434-1439, (1999).
Fallingborg, J. et al., “Effect of Olsalazine and Mesalazine on Intraluminal pH of the Duodenum and Proximal Jerjunum in Healthy Humans,”Scan. J. Gastroentero., vol. 29, No. 6, pp. 498-500, (1994).
Farup, P. et al., “Mesalazine 4 g Daily Given as Prolonged-Release Granules Twice Daily and Four Times Daily Is at Least as Effective as Prolonged-Release Tablets Four Times Daily in Patients with Ulcerative Colitis,”Inflamm. Bowel Dis., vol. 7, No. 3, pp. 237-242, (2001).
Fernandez-Banares et al., “Collagenous and Lymphocytic Colitis: Evaluation of Clinical and Histological Features, Response to Treatment, and Long-Term Follow-Up,”Am. J. Gastroenterol., vol. 98, No. 2, pp. 395-402, (2003).
Fischer, C. et al. “Disposition of 5-Aminosalicylic Acid, the Active Metabolite of Sulphasalazine, in Man,”Eur. J. Clin. Pharamcol., vol. 25, pp. 511-515, (1983).
Florent, C. et al., “Placebo-Controlled Clinical Trial of Mesalazine in the Prevention of Early Endoscopic Recurrences After Recurrences After Resection for Crohn's Disease,”Eur J. Gastroen. Hepat., vol. 8, No. 3, pp. 229-233, (1996).
Fockens, P. et al., “Comparison of the Efficacy and Safety of 1.5 Compared with 3.0 g oral Slow-Releas

Affiliated with

Also associated with

Rating

Formulations and methods of treating inflammatory bowel disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulations and methods of treating inflammatory bowel disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations and methods of treating inflammatory bowel disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2686239